Treatment and survival analyses of malignant mesothelioma in Japan

Figures & data

Figure 1. Overall survival of patients with malignant pleural mesothelioma according to histological subtype.

Figure 2. Overall survival of patients with malignant pleural mesothelioma according to treatment modality. E. both radical surgery and systemic chemotherapy, F. radical surgery but no systemic chemotherapy, G. systemic chemotherapy but no radical surgery, and H. without radical surgery or systemic chemotherapy.

Figure 3. Overall survival of patients with malignant mesothelioma according to year of death. A. patients died between 2006 and 2008, B. patients died between 2003 and 2005.

Table I. Univariate analysis of clinical variables and survival of patients with malignant pleural mesothelioma (Log-rank test).

Factor		N	MST^§ (95% CI)	p
Gender				0.6435
Male	654	7.9 (7.2–8.5)
namest="col-1" nameend="col-3">Female	135	7.7 (6.3–9.0)
Age				< 0.001
< 70	438	10.0 (8.6–11.4)
≥70	351	6.1 (5.0–7.1)
Subtype				< 0.001
Epithelioid	326	10.0 (8.4–11.5)
namest="col-1" nameend="col-3">Non-epithelioid	251	6.3 (5.1–7.5)
Stage				< 0.001
I–III	451	9.4 (8.5–10.3)
namest="col-1" nameend="col-3">IV	152	3.8 (3.0–4.6)

CI, confidence interval. ^§Median survival time (months).

Table II. Multivariate analysis of clinical variables and survival of patients with malignant pleural mesothelioma.

Factor	Exp (β)	95% CI	p
Gender	1.55	1.20–2.01	0.001
Age	1.28	1.05–1.57	0.016
Subtype	1.74	1.45–2.09	< 0.001
Stage	1.83	1.48–2.27	< 0.001
Surgery	1.31	1.03–1.66	0.026
Chemotherapy	1.58	1.31–1.91	< 0.001

CI, confidence interval.